Cardiometabolic Risk Reduction: A Review of Clinical Guidelines and the Role of SGLT-2 Inhibitors.
J Fam Pract
; 70(6S): S1-S6, 2021 07.
Article
in English
| MEDLINE | ID: covidwho-1372160
ABSTRACT
LEARNING OBJECTIVES:
At the end of the activity, participants will be able to ⢠Identify how heart failure (HF), chronic kidney disease (CKD), and type 2 diabetes mellitus (T2DM) and associated cardiovascular (CV) risks are interconnected. ⢠Initiate guideline-recommended therapy to reduce CV risk in patients with HF, CKD, and/or T2DM. ⢠Apply evidence for sodium-glucose cotransporter-2 inhibitors (SGLT-2 inhibitors) to clinical practice, based on recent and emerging trials. ⢠Review evidence suggesting increased incidence and severity of COVID-19 infection in patients with diabetes.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Cardiovascular Diseases
/
Sodium-Glucose Transporter 2 Inhibitors
Type of study:
Observational study
/
Prognostic study
Limits:
Humans
Language:
English
Journal:
J Fam Pract
Year:
2021
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS